AU2001248281A1 - Pharmaceutical composition of modified pna molecules - Google Patents

Pharmaceutical composition of modified pna molecules

Info

Publication number
AU2001248281A1
AU2001248281A1 AU2001248281A AU4828101A AU2001248281A1 AU 2001248281 A1 AU2001248281 A1 AU 2001248281A1 AU 2001248281 A AU2001248281 A AU 2001248281A AU 4828101 A AU4828101 A AU 4828101A AU 2001248281 A1 AU2001248281 A1 AU 2001248281A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
pna molecules
modified pna
modified
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001248281A
Inventor
Jeppe Viggo Christensen
Edward Kristensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pantheco AS
Original Assignee
Pantheco AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantheco AS filed Critical Pantheco AS
Publication of AU2001248281A1 publication Critical patent/AU2001248281A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2001248281A 2000-04-06 2001-04-06 Pharmaceutical composition of modified pna molecules Abandoned AU2001248281A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000587 2000-04-06
DKPA200000587 2000-04-06
PCT/DK2001/000238 WO2001076636A2 (en) 2000-04-06 2001-04-06 Pharmaceutical composition of modified pna molecules

Publications (1)

Publication Number Publication Date
AU2001248281A1 true AU2001248281A1 (en) 2001-10-23

Family

ID=8159411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001248281A Abandoned AU2001248281A1 (en) 2000-04-06 2001-04-06 Pharmaceutical composition of modified pna molecules

Country Status (4)

Country Link
US (1) US20040072743A1 (en)
EP (1) EP1296718A1 (en)
AU (1) AU2001248281A1 (en)
WO (1) WO2001076636A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0026924D0 (en) 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
AU2002218151A1 (en) * 2000-11-24 2002-06-03 Pantheco A/S Pna analogues
AU2002216946A1 (en) * 2001-01-05 2002-07-16 Pantheco A/S Modified pna molecules
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
ES2367289T3 (en) 2004-07-02 2011-11-02 Avi Biopharma, Inc. ANTIBENTITER ANTIBACTERIAL METHOD AND COMPOSITE.
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007009094A2 (en) * 2005-07-13 2007-01-18 Avi Biopharma, Inc. Antisense antibacterial method and compound
FR2953555B1 (en) * 2009-12-07 2012-04-06 Snecma ASSEMBLY OF A RETAINING RING AND A HOLDING FLANGE FOR SAID JOB
CA2799501C (en) 2010-05-28 2022-02-15 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
CN101891804B (en) * 2010-06-21 2012-12-26 中国人民解放军第四军医大学 Antisense peptide nucleic acid of cell penetrating peptide-mediated antibacterial RNA polymerase sigma 70 factor gene rpoD
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
AU2012340390B2 (en) 2011-11-18 2016-11-24 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
WO2013142087A1 (en) 2012-03-20 2013-09-26 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
SG10201710369RA (en) * 2013-03-15 2018-01-30 Techulon Inc Antisense molecules for treatment of staphylococcus aureus infection
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834430A (en) * 1995-05-31 1998-11-10 Biosynth S.R.L. Potentiation of antibiotics
EP0975370B9 (en) * 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
AU7773000A (en) * 1998-11-11 2001-04-23 Pantheco A/S Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or amorpholino

Also Published As

Publication number Publication date
WO2001076636A3 (en) 2002-02-28
US20040072743A1 (en) 2004-04-15
EP1296718A1 (en) 2003-04-02
WO2001076636A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
AU781269C (en) Pharmaceutical compositions
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2001233081A1 (en) Composition for treatment of stress
AU2002302147A1 (en) Pharmaceutical composition
AU2001248281A1 (en) Pharmaceutical composition of modified pna molecules
AU2002258221A1 (en) Medicinal composition
AU2001290239A1 (en) Medicinal composition
AU5460800A (en) Pharmaceutical transdermal compositions
AU2001273919A1 (en) Pharmaceutical compositions
AU2002230781A1 (en) Pharmaceutical uses and synthesis of benzobicyclooctanes
AU4085201A (en) Pharmaceutical composition
AU2002244865A1 (en) Pharmaceutical composition of ibuprofen
AU2002246659A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2002246658A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU4914400A (en) Novel pharmaceutical composition
AU2002216946A1 (en) Modified pna molecules
AU3586401A (en) Pharmaceutical composition
AU2001278705A1 (en) Pharmaceutical composition
AUPQ884500A0 (en) Novel therapeutic molecules and uses therefor - III
AU2001260083A1 (en) New pharmaceutical composition and the process for its preparation
AU2001259564A1 (en) Pharmaceutical compositions and methods for use
AUPR529701A0 (en) Pharmaceutical composition
AU2001276556A1 (en) Novel pharmaceutical use of quinnoline derivatives